Goldman Sachs Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $25
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.
Goldman Sachs analyst David Roman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $28 to $25.